Colorado Drug Price Board Says J&J’s Stelara is Unaffordable

• Panel to vote next on whether to enact Stelara payment limit
• State battling lawsuit from Amgen over February Enbrel vote

A blockbuster arthritis drug from Johnson & Johnson could soon see a limit on what Colorado health plans pay for the product after the state review board determined the treatment is “unaffordable” for patients.

The five-member Colorado Prescription Drug Affordability Board voted Friday to grant this designation to Stelara, an injectable drug used to treat conditions like moderate to severe plaque psoriasis and Crohn’s disease.

https://news.bloomberglaw.com/health-law-and-business/colorado-drug-pricing-board-says-j-js-stelara-is-unaffordable